GPR35; | |
RECQL; TDP1; BLM; APOBEC3G; CTDSP1; PIK3CG; GLO1; HPGD; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALDH1A1; NOX4; USP2; APEX1; POLB; | |
ACHE; GAA; | |
DUSP3; | |
TOP2A; | |
AKT1; MET; INSR; CSNK2A1; DAPK1; SYK; FLT3; SRC; IGF1R; PTK2; BRAF; AURKB; AURKA; FLT4; EPHB4; MAP3K8; TEK; PDGFRB; GSK3B; PLK4; ERBB2; EGFR; NUAK1; MYLK; KDR; PLK1; | |
CA7; CA5A; CA14; CA5B; CA1; CA12; CA9; CA13; CA4; CA6; CA2; | |
AR; | |
ESRRA; | |
KDM4E; | |
ALOX5; TYR; XDH; | |
BACE1; | |
AHR; HIF1A; TP53; | |
ABCC1; ABCG2; | |
SLC22A6; | |
SMAD3; LMNA; MAPT; HBB; THPO; APP; HSPA1A; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.293E-11 | 5.313E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, HBB, NOX4 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 8.338E-11 | 1.666E-08 | EGFR, ERBB2, INSR, MET, NOX4, PDGFRB, PIK3CG, PTK2, SRC, TEK, THPO |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 2.049E-10 | 3.881E-08 | EGFR, ERBB2, INSR, KDR, SYK |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.084E-10 | 7.290E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.338E-09 | 2.172E-07 | ALOX15, APP, BRAF, EGFR, FLT4, KDR, NOX4, PDGFRB, SRC, TEK, THPO |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.598E-09 | 2.522E-07 | EGFR, IGF1R, INSR, KDR, PTK2, SRC, SYK |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.652E-09 | 4.039E-07 | ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, HBB, XDH |
MF | GO:0005488; binding | GO:0020037; heme binding | 6.154E-09 | 8.482E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, HBB, NOX4, SRC |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.780E-08 | 2.222E-06 | APOBEC3G, AR, BLM, CA1, CA12, CA13, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, ESRRA, GLO1, L3MBTL1, SMAD3, TP53 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.172E-08 | 3.775E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.268E-07 | 1.373E-05 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.576E-07 | 1.674E-05 | ABCC1, CA2, CA4, CA9, EGFR, ERBB2, HPGD, SLC22A6, TEK |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 2.152E-07 | 2.231E-05 | FLT3, PDGFRB, PTK2, SRC, TEK |
BP | GO:0032502; developmental process | GO:0001525; angiogenesis | 2.292E-07 | 2.354E-05 | CYP1B1, EPHB4, FLT4, HIF1A, KDR, PDGFRB, PIK3CG, PTK2, SYK, TEK |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.019E-07 | 2.961E-05 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 5.045E-07 | 4.735E-05 | FLT3, FLT4, KDR, PDGFRB |
BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 5.679E-07 | 5.240E-05 | AKR1B1, AKT1, APEX1, CYP1B1, EGFR, SRC, TP53 |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 1.088E-06 | 9.673E-05 | AKT1, EGFR, HBB, INSR, SMAD3 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 1.192E-06 | 1.047E-04 | AHR, AKR1B1, AKT1, ALDH1A1, ALOX15, ALOX5, APOBEC3G, APP, AR, AURKA, AURKB, BLM, BRAF, CA1, CA13, CA2, CA7, CSNK2A1, DUSP3, EPHB4, ERBB2, FLT3, GLO1, GSK3B, HBB, HIF1A, HPGD, HSD17B1, HSPA1A, LMNA, MAP3K8, MAPT, MYLK, PIK3CG, PLK1, PLK4, PTK2, SMAD3, SRC, SYK, TP53, TYR, XDH |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.283E-06 | 1.107E-04 | AKT1, AURKA, AURKB, BLM, CSNK2A1, L3MBTL1, NUAK1, TP53 |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.287E-06 | 1.107E-04 | ALOX15, EGFR, ERBB2, PDGFRB, SMAD3, TP53 |
BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.748E-06 | 1.426E-04 | ALOX15, ALOX5, HPGD |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.748E-06 | 1.426E-04 | CYP1A2, CYP2C19, CYP2C9 |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 1.853E-06 | 1.500E-04 | ABCG2, AHR, APP, EGFR, ERBB2, FLT4, IGF1R, INSR, SMAD3, SYK |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.167E-06 | 1.716E-04 | CYP1A1, PDGFRB, POLB, TP53 |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 3.049E-06 | 2.338E-04 | FLT3, FLT4, KDR |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 3.164E-06 | 2.401E-04 | AKT1, CYP1B1, DAPK1, GSK3B, HPGD, MAPT, NOX4, PDGFRB, SMAD3, SRC, TOP2A, TP53, XDH |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.184E-06 | 2.407E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 5.029E-06 | 3.579E-04 | AKR1B1, APEX1, BLM, BRAF, CYP1B1, EGFR, KDR, SRC, TP53 |
CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 6.212E-06 | 4.214E-04 | ACHE, AKR1B1, APEX1, APP, AURKA, CA4, EGFR, ERBB2, HSPA1A, NOX4, SRC, TYR, USP2 |
BP | Unclassified; | GO:0006461; protein complex assembly | 6.355E-06 | 4.285E-04 | ACHE, AR, BLM, BRAF, GSK3B, HBB, HSD17B10, HSPA1A, IGF1R, INSR, MAPT, PTK2, SLC22A6, SMAD3, SRC, TEK, TP53 |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 7.067E-06 | 4.649E-04 | AKT1, AR, DAPK1, HSPA1A, LMNA, SRC |
BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 7.270E-06 | 4.725E-04 | APP, EGFR, MAPT |
BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 7.270E-06 | 4.725E-04 | BLM, RECQL, TP53 |
BP | GO:0009987; cellular process | GO:0070507; regulation of microtubule cytoskeleton organization | 7.548E-06 | 4.877E-04 | AURKA, GSK3B, HSPA1A, MAPT, MET, PLK1, PLK4 |
BP | GO:0050896; response to stimulus | GO:0042542; response to hydrogen peroxide | 9.289E-06 | 5.812E-04 | AKR1B1, APEX1, CYP1B1, HBB, PDGFRB, SRC |
BP | GO:0032502; developmental process | GO:0007568; aging | 9.612E-06 | 5.939E-04 | AKT1, APEX1, AURKB, CYP1A1, NOX4, PDGFRB, POLB, TP53 |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.101E-05 | 6.695E-04 | ABCC1, ALOX15, ALOX5, SYK |
CC | GO:0043226; organelle | GO:0051233; spindle midzone | 1.101E-05 | 6.695E-04 | APP, AURKA, AURKB, PLK1 |
BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 1.188E-05 | 7.069E-04 | FLT3, KDR, PDGFRB, PTK2, TEK |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.185E-05 | 7.069E-04 | ABCG2, ACHE, AKT1, APOBEC3G, BLM, FLT3, FLT4, HPGD, MAPT, SLC22A6, SMAD3, TOP2A, TYR, XDH |
MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 1.188E-05 | 7.069E-04 | EGFR, ERBB2, MET, PDGFRB, PIK3CG |
BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 1.254E-05 | 7.361E-04 | EPHB4, GAA, INSR, PTK2 |
BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 1.457E-05 | 8.418E-04 | AKR1B1, AKT1, EGFR, HSD17B2, KDR, PDGFRB, SLC22A6, SRC, TP53 |
MF | GO:0005488; binding | GO:0002039; p53 binding | 1.587E-05 | 9.091E-04 | BLM, GSK3B, HIF1A, NUAK1, TP53 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.606E-05 | 9.177E-04 | CYP19A1, CYP1A1, CYP2C19, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.885E-05 | 1.055E-03 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.005E-05 | 1.108E-03 | APEX1, POLB |
BP | GO:0050896; response to stimulus | GO:0034405; response to fluid shear stress | 2.263E-05 | 1.238E-03 | AKT1, CA2, PDGFRB, SRC |
BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 2.371E-05 | 1.291E-03 | AKR1B1, AKT1, EGFR, HPGD, PDGFRB |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.443E-05 | 1.327E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 2.675E-05 | 1.445E-03 | AKT1, APP, EGFR, PLK1, SMAD3, SRC |
BP | GO:0022610; biological adhesion | GO:0033628; regulation of cell adhesion mediated by integrin | 3.100E-05 | 1.654E-03 | CYP1B1, PIK3CG, PTK2, SYK |
BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 3.231E-05 | 1.703E-03 | AKT1, AURKA, GSK3B, HSPA1A, PLK1 |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 3.231E-05 | 1.703E-03 | AKR1B1, AKT1, AR, EGFR, SRC |
BP | GO:0032501; multicellular organismal process | GO:0045780; positive regulation of bone resorption | 3.861E-05 | 2.002E-03 | CA2, EGFR, SYK |
BP | GO:0065007; biological regulation | GO:0043281; regulation of cysteine-type endopeptidase activity involved in apoptotic process | 4.024E-05 | 2.073E-03 | AKT1, CSNK2A1, DAPK1, MAPT, SMAD3, SRC, XDH |
BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 4.027E-05 | 2.073E-03 | AR, CA2, CA9, EGFR, HIF1A, MET, SMAD3, SRC |
BP | GO:0008283; cell proliferation | GO:0001938; positive regulation of endothelial cell proliferation | 4.315E-05 | 2.195E-03 | AKT1, FLT4, HIF1A, KDR, TEK |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 4.737E-05 | 2.393E-03 | ALOX15, ALOX5, HPGD |
BP | GO:0008152; metabolic process | GO:1901575; organic substance catabolic process | 5.196E-05 | 2.589E-03 | ACHE, AKT1, ALDH1A1, APOBEC3G, AURKA, AURKB, BACE1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GAA, GSK3B, HSD17B10, HSPA1A, PLK1, TP53, USP2, XDH |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 5.275E-05 | 2.622E-03 | APP, BACE1, EGFR, INSR, KDR, SLC22A6, SRC, TEK |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.999E-05 | 2.916E-03 | CA2, CA7 |
BP | GO:0051179; localization | GO:0051222; positive regulation of protein transport | 6.013E-05 | 2.916E-03 | ACHE, APP, EGFR, ERBB2, GSK3B, HIF1A, SMAD3, SRC, SYK, TP53 |
BP | GO:0050896; response to stimulus | GO:0071320; cellular response to cAMP | 7.548E-05 | 3.557E-03 | APEX1, APP, NOX4, PIK3CG |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 7.891E-05 | 3.679E-03 | AHR, AURKA, BRAF, EGFR, ERBB2, HIF1A, SMAD3, TOP2A, TP53, TYR |
BP | GO:0008152; metabolic process | GO:0046854; phosphatidylinositol phosphorylation | 8.464E-05 | 3.921E-03 | EGFR, ERBB2, MET, PDGFRB, PIK3CG |
CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 9.499E-05 | 4.382E-03 | AURKA, AURKB, PLK1, POLB |
BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 1.026E-04 | 4.663E-03 | AKR1B1, ALDH1A1, ALOX15, APP, CYP19A1, CYP1A1, CYP1B1, HIF1A, TYR |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.069E-04 | 4.831E-03 | AKT1, HIF1A, LMNA, SRC, TP53 |
BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 1.102E-04 | 4.969E-03 | AHR, AKT1, APEX1, APP, AR, AURKB, BLM, CSNK2A1, CTDSP1, DAPK1, DUSP3, ESRRA, GSK3B, HIF1A, HSPA1A, IGF1R, L3MBTL1, MAPT, MET, PIK3CG, PLK1, SMAD3, SRC, TP53, USP2, XDH |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.196E-04 | 5.283E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.196E-04 | 5.283E-03 | CYP1A2, CYP2C9 |
MF | GO:0005488; binding | GO:0051425; PTB domain binding | 1.196E-04 | 5.283E-03 | APP, INSR |
MF | GO:0005488; binding | GO:0005497; androgen binding | 1.196E-04 | 5.283E-03 | ALDH1A1, AR |
BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 1.277E-04 | 5.588E-03 | HIF1A, SMAD3, TP53 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.278E-04 | 5.588E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
BP | GO:0008152; metabolic process | GO:0006650; glycerophospholipid metabolic process | 1.366E-04 | 5.902E-03 | ACHE, ALOX15, CSNK2A1, EGFR, ERBB2, MET, PDGFRB, PIK3CG |
BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 1.439E-04 | 6.181E-03 | ABCG2, APP, CA12, CA2, CA7, EGFR, GPR35, HIF1A, PIK3CG, SMAD3, TP53 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.437E-04 | 6.181E-03 | AHR, AKR1B1, AKT1, ALOX5, APEX1, AR, AURKA, AURKB, BLM, CSNK2A1, CTDSP1, DUSP3, ESRRA, GSK3B, HIF1A, HPGD, HSPA1A, L3MBTL1, LMNA, NUAK1, PLK1, POLB, RECQL, SMAD3, SRC, TOP2A, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.464E-04 | 6.216E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 1.788E-04 | 7.457E-03 | AHR, AR, GSK3B, SMAD3, TP53 |
BP | GO:0065007; biological regulation | GO:0051881; regulation of mitochondrial membrane potential | 1.985E-04 | 8.106E-03 | AKT1, KDR, MAPT, SRC |
BP | GO:0008152; metabolic process | GO:2000573; positive regulation of DNA biosynthetic process | 1.985E-04 | 8.106E-03 | AURKB, NOX4, PDGFRB, SRC |
MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 1.988E-04 | 8.106E-03 | BLM, RECQL |
CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 1.988E-04 | 8.106E-03 | AURKA, AURKB |
BP | GO:0065007; biological regulation | GO:0060249; anatomical structure homeostasis | 2.031E-04 | 8.218E-03 | AKR1B1, APEX1, BLM, GAA, HIF1A, NOX4, SRC |
BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 2.094E-04 | 8.399E-03 | AKR1B1, APEX1, CYP1B1, KDR, TP53 |
BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 2.123E-04 | 8.444E-03 | AKT1, APP, AURKA, AURKB, CSNK2A1, CYP1B1, DUSP3, GPR35, GSK3B, IGF1R, MAPT, MET, PLK1, SRC, TP53 |
MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 2.370E-04 | 9.282E-03 | APEX1, BLM, POLB, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 2.387E-04 | 9.299E-03 | CYP1B1, FLT4, HIF1A |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 2.387E-04 | 9.299E-03 | APP, GSK3B, IGF1R |
BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 2.440E-04 | 9.487E-03 | CYP1A2, EGFR, ESRRA, HPGD, PDGFRB |
BP | GO:0050896; response to stimulus | GO:0071214; cellular response to abiotic stimulus | 2.485E-04 | 9.630E-03 | AKT1, AURKB, BLM, EGFR, MYLK, NOX4, TP53 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.080E-23 | 7.838E-20 | CA1, CA12, CA13, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.941E-19 | 1.609E-15 | CA1, CA12, CA13, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, HBB |
MF | GO:0005488; binding | GO:0005524; ATP binding | 2.347E-16 | 3.006E-13 | ABCC1, ABCG2, AKT1, AURKA, AURKB, BLM, BRAF, CSNK2A1, DAPK1, EGFR, EPHB4, ERBB2, FLT3, FLT4, GSK3B, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MET, MYLK, NUAK1, PDGFRB, PIK3CG, PLK1, PLK4, PTK2, RECQL, SRC, SYK, TEK, TOP2A, TP53 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.654E-16 | 4.699E-13 | CA1, CA12, CA13, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PIK3CG; PIK3CG; AURKA; PLK1 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; MAPT; ACHE; ACHE; ACHE; INSR; APP |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ACHE; IGF1R; INSR |
C00-D49: Neoplasms | Melanoma | C43 | BRAF; EGFR; TYR; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE |
NA: NA | Geographic retinal atrophy | NA | APP |
C00-D49: Neoplasms | Glioma | C71 | PIK3CG; EGFR; EGFR; KDR; APP |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; EGFR; KDR; PLK1 |
C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | ERBB2; KDR |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; SRC; IGF1R |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B; SRC |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; EGFR; EGFR; EGFR; TP53; KDR; KDR |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B; PDGFRB; INSR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | PIK3CG; KDR |
C00-D49: Neoplasms | Gastric cancer | C16 | ERBB2; EGFR; EGFR; KDR; KDR |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
NA: NA | Male hypogonadism | NA | AR |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; INSR |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG; ERBB2; PLK1 |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; IGF1R; PDGFRB; EGFR; EGFR; KDR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
C00-D49: Neoplasms | Solid tumors | NA | BRAF |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; SYK; PIK3CG; FLT3; CA9; SRC; IGF1R; PTK2; AURKB; AURKA; FLT4; TEK; PDGFRB; HIF1A; ERBB2; EGFR; TP53; KDR; KDR; KDR; PLK1; PLK1; TOP2A |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
C00-D49: Neoplasms | Breast cancer | C50 | AR; PIK3CG; FLT3; FLT3; CA9; IGF1R; INSR; CYP19A1; ERBB2; ERBB2; ERBB2; EGFR; EGFR; EGFR; KDR; KDR; KDR |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; ESRRA; ALOX5; SYK; TYR |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2; MYLK |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR; KDR; KDR; KDR; KDR |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
NA: NA | Edema | NA | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | PIK3CG; PIK3CG |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TEK; KDR |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; PIK3CG; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; PIK3CG; FLT3; FLT4; ERBB2; EGFR; PLK1 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
NA: NA | Upper abdominal bloating | NA | ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ABCC1; ESRRA; ALOX5; PIK3CG; TEK |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; PIK3CG |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; GSK3B; CSNK2A1; SYK; PIK3CG; CA1; FLT3; FLT3; CA9; ACHE; SRC; IGF1R; PTK2; BRAF; BRAF; AURKA; FLT4; EPHB4; TEK; HIF1A; ERBB2; ERBB2; EGFR; TP53; KDR; PLK1; APP |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; KDR |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PIK3CG; PIK3CG; INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; INSR |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | PIK3CG; CYP2C9 |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; TEK |
C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB; APP |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; BRAF; AURKA; TP53 |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; ERBB2; EGFR |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | FLT4; EGFR |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; PIK3CG; PIK3CG; CA9; INSR; HIF1A; ERBB2; EGFR; PLK1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | ERBB2 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; ERBB2; EGFR; EGFR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; BRAF |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
NA: NA | Enthesopathy | NA | PIK3CG |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; TP53 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ESRRA; ALOX5; ALOX5; SYK; SYK; ERBB2 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; AURKA; TP53; TP53; PLK1 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
NA: NA | HIV infections | NA | AHR |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; ERBB2; EGFR; EGFR; TP53; KDR |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1; PIK3CG |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; FLT4; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
C00-D49: Neoplasms | Thyroid cancer | C73 | BRAF; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE |
NA: NA | Angioedema | NA | PIK3CG |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |